First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects
Completed
Pfizer
Phase 1
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
single oral doses of PF-06882961 in healthy adult subjects. This is the first clinical study
of PF-06882961.
A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961
Completed
Pfizer
Phase 1
This open label study will evaluate the pharmacokinetics (PK) following single oral doses of
different formulations of PF-06882961, including controlled release (CR) tablets at 2 release
rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in
healthy adult subjects.
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
Completed
Pfizer
Phase 1
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants
will receive an investigational product or placebo for 28 days.
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
Completed
Pfizer
Phase 2
This multicenter, randomized, double-blind, placebo controlled, parallel group study is being
conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of
multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM)
inadequately controlled on metformin and/or diet and exercise. In addition, the study is
intended to enable selection of efficacious doses for future clinical development of
PF-06882961.
Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961
Completed
Pfizer
Phase 1
This study is a Phase 1, open-label, non-randomized, 2-period, fixed sequence study to
characterize the metabolic profile and routes of excretion of oral [14C]PF-06882961 and to
evaluate the absolute oral bioavailability of PF-06882961 and fraction absorbed of
[14C]PF-06882961 in reference to intravenous [14C]PF-06882961 in healthy male participants.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
